Načítá se...
Naming Convention, Interchangeability, and Patient Interest in Biosimilars
Although biosimilars may offer cost savings over their comparable biologics, use of biosimilars in the United States remains relatively low. This study investigates two barriers to uptake of biosimilars in the United States. First, the U.S. Food and Drug Administration requires that four-letter suff...
Uloženo v:
| Vydáno v: | Diabetes Spectr |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Diabetes Association
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7428664/ https://ncbi.nlm.nih.gov/pubmed/32848349 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/ds19-0065 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|